Literature DB >> 28876896

Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors.

Lars Dittus1, Thilo Werner1, Marcel Muelbaier1, Marcus Bantscheff1.   

Abstract

Chemoproteomics profiling of kinase inhibitors with kinobeads enables the assessment of inhibitor potency and selectivity for endogenously expressed protein kinases in cell lines and tissues. Using a small panel of targeted covalent inhibitors, we demonstrate the importance of measuring covalent target binding in live cells. We present a differential kinobeads profiling strategy for covalent kinase inhibitors where a compound is added either to live cells or to a cell extract that enables the comprehensive assessment of inhibitor selectivity for covalent and noncovalent targets. We found that Acalabrutinib, CC-292, and Ibrutinib potently and covalently bind TEC family kinases, but only Ibrutinib also potently binds to BLK. ZAK was identified as a submicromolar affinity Ibrutinib off-target due to covalent modification of Cys22. In contrast to Ibrutinib, 5Z-7-Oxozeaenol reacted with Cys150 next to the DFG loop, demonstrating an alternative route to covalent inactivation of this kinase, e.g., to inhibit canonical TGF-β dependent processes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28876896     DOI: 10.1021/acschembio.7b00617

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  9 in total

1.  Impact of Mass Spectrometry-Based Technologies and Strategies on Chemoproteomics as a Tool for Drug Discovery.

Authors:  Ryan A McClure; Jon D Williams
Journal:  ACS Med Chem Lett       Date:  2018-07-03       Impact factor: 4.345

2.  Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.

Authors:  Suman Rao; Deepak Gurbani; Guangyan Du; Robert A Everley; Christopher M Browne; Apirat Chaikuad; Li Tan; Martin Schröder; Sudershan Gondi; Scott B Ficarro; Taebo Sim; Nam Doo Kim; Matthew J Berberich; Stefan Knapp; Jarrod A Marto; Kenneth D Westover; Peter K Sorger; Nathanael S Gray
Journal:  Cell Chem Biol       Date:  2019-04-11       Impact factor: 8.116

3.  Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.

Authors:  Mark M Moasser
Journal:  Cancer Res       Date:  2022-08-16       Impact factor: 13.312

Review 4.  The emerging role of mass spectrometry-based proteomics in drug discovery.

Authors:  Felix Meissner; Jennifer Geddes-McAlister; Matthias Mann; Marcus Bantscheff
Journal:  Nat Rev Drug Discov       Date:  2022-03-29       Impact factor: 112.288

Review 5.  Proteomics-based target identification of natural products affecting cancer metabolism.

Authors:  Makoto Muroi; Hiroyuki Osada
Journal:  J Antibiot (Tokyo)       Date:  2021-07-20       Impact factor: 2.649

Review 6.  An overview of kinase downregulators and recent advances in discovery approaches.

Authors:  Beilei Wang; Hong Wu; Chen Hu; Haizhen Wang; Jing Liu; Wenchao Wang; Qingsong Liu
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

Review 7.  Targeting Protein Kinases Degradation by PROTACs.

Authors:  Fei Yu; Ming Cai; Liang Shao; Jihong Zhang
Journal:  Front Chem       Date:  2021-06-30       Impact factor: 5.221

Review 8.  Drug Discovery in Liver Disease Using Kinome Profiling.

Authors:  Bingting Yu; Ruslan Mamedov; Gwenny M Fuhler; Maikel P Peppelenbosch
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

9.  Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers.

Authors:  Marcia R Campbell; Ana Ruiz-Saenz; Elliott Peterson; Christopher Agnew; Pelin Ayaz; Sam Garfinkle; Peter Littlefield; Veronica Steri; Julie Oeffinger; Maryjo Sampang; Yibing Shan; David E Shaw; Natalia Jura; Mark M Moasser
Journal:  Cell Rep       Date:  2022-02-01       Impact factor: 9.995

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.